{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:46:14Z","timestamp":1792205174360,"version":"4.4.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.schres.2012.12.006","type":"journal-article","created":{"date-parts":[[2013,1,8]],"date-time":"2013-01-08T23:34:28Z","timestamp":1357688068000},"page":"105-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Can we inflate effect size and thus increase chances of producing \u201cpositive\u201d results if we raise the baseline threshold in schizophrenia trials?"],"prefix":"10.1016","volume":"144","author":[{"given":"Toshi A.","family":"Furukawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.schres.2012.12.006_bb0005","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1017\/S1461145711001738","article-title":"Placebo-related effects in clinical trials in schizophrenia: what is driving this phenomenon and what can be done to minimize it?","volume":"15","author":"Alphs","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"Pt 3","key":"10.1016\/j.schres.2012.12.006_bb0010","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1348\/000712608X377117","article-title":"Standardized or simple effect size: what should be reported?","volume":"100","author":"Baguley","year":"2009","journal-title":"Br. J. Psychol."},{"issue":"1","key":"10.1016\/j.schres.2012.12.006_bb0015","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1177\/109442810141003","article-title":"Correcting the effect size of d for range restriction and unreliability","volume":"4","author":"Bobko","year":"2001","journal-title":"Organ. Res. Methods"},{"issue":"10","key":"10.1016\/j.schres.2012.12.006_bb0020","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1176\/appi.ajp.162.10.1879","article-title":"Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia","volume":"162","author":"Breier","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2012.12.006_bb0025","series-title":"Statistical Power Analysis in the Behavioral Sciences","author":"Cohen","year":"1988"},{"issue":"1","key":"10.1016\/j.schres.2012.12.006_bb0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/00004850-200015010-00002","article-title":"Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group","volume":"15","author":"Colonna","year":"2000","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.schres.2012.12.006_bb0035","first-page":"CD001359","article-title":"Olanzapine for schizophrenia","author":"Duggan","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2012.12.006_bb0040","series-title":"Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice","first-page":"249","article-title":"Measurement of patients' experience","author":"Furukawa","year":"2008"},{"key":"10.1016\/j.schres.2012.12.006_bb0045","author":"Higgins"},{"issue":"2","key":"10.1016\/j.schres.2012.12.006_bb0050","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"issue":"2\u20133","key":"10.1016\/j.schres.2012.12.006_bb0055","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2012.12.006_bb0060","first-page":"CD001357","article-title":"Amisulpride for schizophrenia","author":"Mota","year":"2002","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.schres.2012.12.006_bb0065","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychol. Rep."},{"key":"10.1016\/j.schres.2012.12.006_bb0070","series-title":"SPSS for Windows Version 18.0","author":"SPSS Inc.","year":"2009"},{"issue":"4","key":"10.1016\/j.schres.2012.12.006_bb0075","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/ajp.154.4.457","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial","volume":"154","author":"Tollefson","year":"1997","journal-title":"Am. J. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996412006809?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996412006809?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T18:37:38Z","timestamp":1760294258000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996412006809"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":15,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0920996412006809"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2012.12.006","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Can we inflate effect size and thus increase chances of producing \u201cpositive\u201d results if we raise the baseline threshold in schizophrenia trials?","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2012.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}